By Casey Branham and Dr. Eugene B. Cone

Prostate cancer is one of the most common cancers among men, with 1 in 8 diagnosed in their lifetime. In 2026 alone, the American Cancer Society estimates about 333,830 new cases. Despite its widespread presence, the methods for diagnosing and treating prostate cancer have remained relatively unchanged for decades—until recently.

Traditionally, treatment focuses on either monitoring the disease or radical treatment of the entire gland, either surgical removal or whole-gland radiation. These approaches can have significant quality of life consequences, with side effects including urinary incontinence, erectile dysfunction, urgency and frequency for urination and bowel movements, logistical inconvenience, and prolonged recovery times.


In hospitals today, prostate cancer care is at a tipping point. As innovation rapidly expands and patients become more engaged in treatment decisions, they are increasingly seeking care that prioritizes function and minimizes disruption to daily life. At the same time, many hospitals find gaps in technology, training and resources needed to fully support newer, more advanced treatment approaches.

The evolution of care
Advances in imaging and precision medicine are reshaping the landscape of prostate cancer diagnosis and treatment. Improvements in imaging, including AI-assisted radiology, are enhancing clinicians’ ability to detect, localize and characterize prostate tumors with greater accuracy. These tools complement clinician expertise by enhancing interpretation of complex imaging data. In some cases, AI systems have helped detect cancerous lesions that were initially missed in traditional reviews. These AI models are trained on large datasets, including MRI scans, radiologist interpretations and pathology correlations.

Once the focus shifts to treatment, emerging therapies aim to treat only the cancerous portion of the prostate, preserving as much healthy tissue as possible and marking a meaningful shift toward more personalized care.

Among these approaches focal ablation of prostate cancer is gaining popularity and acceptance; high-intensity focused ultrasound (HIFU) uses targeted ultrasound waves to heat and destroy cancer cells with millimeter-level precision, while cryoablation uses super-cooled ice balls to freeze the area of interest. HIFU is an incision-free procedure while cryoablation leaves only small puncture marks from the needle probes, with both surgeries designed to reduce damage to surrounding tissues and lower the risk of side effects. According to clinical data across focal ablation, the risk of short-term incontinence is only 2-3%, compared to almost 100% for prostatectomy, and 95% of patients return to their baseline erectile function.

Rad Oncology Homepage